Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Kyverna presented full one-year registrational data for miv-cel in stiff person syndrome at the ACTRIMS-ECTRIMS joint meeting, showing durable efficacy with T25FW improvement of 49% at one year and 92% of patients remaining free of chronic immunotherapies. Safety remained well-tolerated, with no high-grade CRS, ICANS, or IEC-HS cases in one-year follow-up; grade 3/4 neutropenia occurred in five patients and serious treatment-related AEs in three, all fully resolved.
Key figures
- Drug Name
- miv-cel (mivocabtagene autoleucel, KYV-101)
- Phase Of Trial
- Phase 2 (registrational, single-arm)
- Walk aid free
- 67% (8/12)
- Sps patients us
- 6000
- Patients treated
- 26
- Patients treated to date
- >100
- T25fw improvement week16
- 46%
- T25fw improvement one year
- 49%
- Grade34 neutropenia patients
- 5
- Six min walk improvement 1yr
- 119 meters
- Serious treatment related aes
- 3
- Six min walk improvement 16wk
- 89 meters
- Pct meaningful improvement week16
- 81% (21/26)
- Pct free of chronic immunotherapies
- 92% (24/26)
- Pct meaningful improvement one year
- 77% (20/26)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.